Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 52

1.

Hemophilia B.

Konkle BA, Huston H, Nakaya Fletcher S.

In: Pagon RA, Adam MP, Ardinger HH, Wallace SE, Amemiya A, Bean LJH, Bird TD, Ledbetter N, Mefford HC, Smith RJH, Stephens K, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2017.
2000 Oct 2 [updated 2017 Jun 15].

2.

Outcome of Clinical Trials with New Extended Half-Life FVIII/IX Concentrates.

Mancuso ME, Santagostino E.

J Clin Med. 2017 Mar 28;6(4). pii: E39. doi: 10.3390/jcm6040039. Review.

3.

Genome editing for inborn errors of metabolism: advancing towards the clinic.

Schneller JL, Lee CM, Bao G, Venditti CP.

BMC Med. 2017 Feb 27;15(1):43. doi: 10.1186/s12916-017-0798-4. Review.

4.

Once-weekly prophylactic dosing of recombinant factor IX improves adherence in hemophilia B.

Djambas Khayat C.

J Blood Med. 2016 Nov 30;7:275-282. eCollection 2016. Review.

5.

Treatment of Patients with Haemophilia [Internet].

Institute for Quality and Efficiency in Health Care.

Cologne, Germany: Institute for Quality and Efficiency in Health Care (IQWiG); 2015 May 28.

6.

Extravascular FIX and coagulation.

Stafford DW.

Thromb J. 2016 Oct 4;14(Suppl 1):35. eCollection 2016. Review.

7.

Aspects of prophylactic treatment of hemophilia.

Ljung R.

Thromb J. 2016 Oct 4;14(Suppl 1):30. eCollection 2016. Review.

8.
10.

Gene therapy: Myth or reality?

Fischer A.

C R Biol. 2016 Jul-Aug;339(7-8):314-8. doi: 10.1016/j.crvi.2016.04.011. Epub 2016 May 31. Review.

11.

The Role of Angiogenesis in Haemophilic Arthropathy: Where Do We Stand and Where Are We Going?

Agapidou A, Stavrakis T, Vlachaki E, Anagnostis P, Vakalopoulou S.

Turk J Haematol. 2016 Jun 5;33(2):88-93. doi: 10.4274/tjh.2016.0031. Review.

12.

Targeting TFPI for hemophilia treatment.

Peterson JA, Maroney SA, Mast AE.

Thromb Res. 2016 May;141 Suppl 2:S28-30. doi: 10.1016/S0049-3848(16)30359-0. Review.

13.

Gene Therapy for Coagulation Disorders.

Swystun LL, Lillicrap D.

Circ Res. 2016 Apr 29;118(9):1443-52. doi: 10.1161/CIRCRESAHA.115.307015. Review.

14.

New developments in the management of moderate-to-severe hemophilia B.

Nazeef M, Sheehan JP.

J Blood Med. 2016 Apr 1;7:27-38. doi: 10.2147/JBM.S81520. eCollection 2016. Review.

15.

Gene therapy: progress and predictions.

Collins M, Thrasher A.

Proc Biol Sci. 2015 Dec 22;282(1821):20143003. doi: 10.1098/rspb.2014.3003. Review.

16.

Adeno-associated virus (AAV) gene delivery in stem cell therapy.

Brown NJ, Hirsch ML.

Discov Med. 2015 Nov;20(111):333-42. Review.

17.

Adeno-associated viral vectors for the treatment of hemophilia.

High KA, Anguela XM.

Hum Mol Genet. 2016 Apr 15;25(R1):R36-41. doi: 10.1093/hmg/ddv475. Epub 2015 Nov 27. Review.

18.

Progress and challenges in viral vector manufacturing.

van der Loo JC, Wright JF.

Hum Mol Genet. 2016 Apr 15;25(R1):R42-52. doi: 10.1093/hmg/ddv451. Epub 2015 Oct 30. Review.

19.

In vivo induction of regulatory T cells for immune tolerance in hemophilia.

Wang X, Terhorst C, Herzog RW.

Cell Immunol. 2016 Mar;301:18-29. doi: 10.1016/j.cellimm.2015.10.001. Epub 2015 Oct 9. Review.

20.

Hemophilia in the managed care setting.

Dalton DR.

Am J Manag Care. 2015 Mar;21(6 Suppl):S123-30. Review.

Supplemental Content

Loading ...
Support Center